Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with R-CHOP or lenalidomide plus R-CHOP in previously untreated high-risk diffuse large B-cell lymphoma
2015-005173-20Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, lenalidomide, rituximab, cyclophosphamide, doxorubicin and 2 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Complete response rate at end of induction therapy. Started Oct 2016; status: completed.
02
Drugs
durvalumablenalidomiderituximabcyclophosphamidedoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2015-005173-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005173-20.